Viatris agreed to acquire Pacira BioSciences for $1.65 billion in cash, betting on a further expansion of its non-opioid pain portfolio. The deal adds commercial-stage assets in pain management at a time when payers and clinicians continue to press for alternatives to opioid-centered care. The transaction is positioned as a portfolio-strengthening move with potential follow-on value if Pacira’s therapies maintain growth and withstand patent expiries. For industry observers, the headline is the scale of generics-and-branded consolidation aimed at clinically differentiated non-opioid categories. Integration details and pipeline plans are expected to determine whether the acquisition meaningfully changes Viatris’ competitive footprint in perioperative and chronic-pain settings.